NCT00485303 - An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Prostatic NeoplasmsProstate Cancer

Interventions

DRUG

Abiraterone acetate

Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.

DRUG

Prednisone

Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.

Trial Locations (14)

10021

Memorial Sloan-Kettering Cancer Center, New York

21205

John Hopkins, Baltimore

90024

UCLA, Los Angeles

94115

UCSF Comprehensive Cancer Center, San Francisco

Unknown

Los Angeles

San Francisco

Baltimore

Boston

New York

Royal Marsden Hospital, Sutton

Sutton

02114

Masachussetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Hospital, Boston